title: Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
abstract: OBJECTIVE
  To evaluate the incidence of Intraoperative Floppy Iris syndrome (IFIS) in relation to the usage of alpha(1)-adrenoceptor antagonists.
  
  
  METHODS
  Prospective, interventional case series.
  
  
  METHODS
  In 2,643 consecutive eyes of 1,968 patients undergoing cataract surgery, occurrence of IFIS and use of alpha(1) antagonists were recorded.
  
  
  RESULTS
  IFIS was observed in 29 eyes (1.1%) of 25 male patients, all of whom were receiving alpha(1) antagonists. In those receiving systemic tamsulosin, alpha(1A) selective antagonist, IFIS developed in 25 (43.1%) of 58 eyes. In those receiving systemic naftopidil, alpha(1A) and alpha(1D) antagonists, IFIS was found in 4 (19.0%) of 21 eyes. There was no case of IFIS in patients who received other systemic alpha(1) antagonists and in eyes treated with bunazosin eyedrops, a nonselective alpha(1) antagonist.
  
  
  CONCLUSIONS
  IFIS occurred in 1.1% of cases treated with systemic alpha(1A)-adrenoceptor antagonists for benign prostatic hypertrophy. Topical nonselective alpha(1) antagonist did not induce IFIS.
authors.affiliation: Department of Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennidai, Tsukuba, Ibaraki 305-8575, Japan. toshika@md.tsukuba.ac.jp
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Oshika
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Mikio
authors.initials: M
authors.lastname: Inamura
authors.forename: Kohtaro
authors.initials: K
authors.lastname: Ohki
authors.forename: Shigeki
authors.initials: S
authors.lastname: Okamoto
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Koyama
authors.forename: Isao
authors.initials: I
authors.lastname: Sakabe
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takahashi
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Fujita
authors.forename: Teruyuki
authors.initials: T
authors.lastname: Miyoshi
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Yasuma
mesh_terms: D000287:Administration, Topical; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D002387:Cataract Extraction; D005260:Female; D006801:Humans; D015994:Incidence; D007431:Intraoperative Complications; D007499:Iris Diseases / Q000139:chemically induced*; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects; D010879:Piperazines / Q000009:adverse effects; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011680:Pupil / Q000187:drug effects*; D011799:Quinazolines / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013577:Syndrome; D000077409:Tamsulosin
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; D011799:Quinazolines; D013449:Sulfonamides; C018176:bunazosin; D000077409:Tamsulosin; C064357:naftopidil